1. Home
  2. ADVM vs PAI Comparison

ADVM vs PAI Comparison

Compare ADVM & PAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • PAI
  • Stock Information
  • Founded
  • ADVM 2006
  • PAI 1973
  • Country
  • ADVM United States
  • PAI United States
  • Employees
  • ADVM N/A
  • PAI N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • PAI Trusts Except Educational Religious and Charitable
  • Sector
  • ADVM Health Care
  • PAI Finance
  • Exchange
  • ADVM Nasdaq
  • PAI Nasdaq
  • Market Cap
  • ADVM 119.6M
  • PAI 118.3M
  • IPO Year
  • ADVM 2014
  • PAI N/A
  • Fundamental
  • Price
  • ADVM $4.25
  • PAI $12.27
  • Analyst Decision
  • ADVM Strong Buy
  • PAI
  • Analyst Count
  • ADVM 6
  • PAI 0
  • Target Price
  • ADVM $27.83
  • PAI N/A
  • AVG Volume (30 Days)
  • ADVM 217.5K
  • PAI 25.0K
  • Earning Date
  • ADVM 11-04-2024
  • PAI 01-01-0001
  • Dividend Yield
  • ADVM N/A
  • PAI 4.78%
  • EPS Growth
  • ADVM N/A
  • PAI N/A
  • EPS
  • ADVM N/A
  • PAI N/A
  • Revenue
  • ADVM $1,000,000.00
  • PAI N/A
  • Revenue This Year
  • ADVM N/A
  • PAI N/A
  • Revenue Next Year
  • ADVM $1,342.84
  • PAI N/A
  • P/E Ratio
  • ADVM N/A
  • PAI N/A
  • Revenue Growth
  • ADVM N/A
  • PAI N/A
  • 52 Week Low
  • ADVM $4.01
  • PAI $10.59
  • 52 Week High
  • ADVM $29.70
  • PAI $12.63
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 29.33
  • PAI 41.23
  • Support Level
  • ADVM $4.42
  • PAI $12.12
  • Resistance Level
  • ADVM $5.11
  • PAI $12.43
  • Average True Range (ATR)
  • ADVM 0.30
  • PAI 0.29
  • MACD
  • ADVM 0.01
  • PAI -0.02
  • Stochastic Oscillator
  • ADVM 21.05
  • PAI 17.35

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed primarily as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.

Share on Social Networks: